Indirect costs in chronic obstructive pulmonary disease: A review of the economic burden on employers and individuals in the United States

International Journal of COPD

Volumn 9, Issue , 2014, Pages 289-300

  Patel, Jeetvan G ^a,b   Nagar, Saurabh P ^b   Dalal, Anand A ^b  

^a UNIVERSITY OF HOUSTON   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Chronic obstructive pulmonary disease; Disability; Economics; Indirect costs; Productivity

Indexed keywords

ABSENTEEISM; CAREGIVER; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST OF ILLNESS; DISABILITY; EMPLOYER; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; INCIDENCE; JOB PERFORMANCE; MEDICAL LEAVE; MORBIDITY; MORTALITY; PHYSICAL INACTIVITY; PREVALENCE; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; UNITED STATES; WORK CAPACITY; WORK DISABILITY; WORKLOAD;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; DISABILITY; ECONOMICS; INDIRECT COSTS; PRODUCTIVITY;

ABSENTEEISM; BED REST; CAREGIVERS; COST OF ILLNESS; DISABILITY EVALUATION; EFFICIENCY; EMPLOYER HEALTH COSTS; HUMANS; INCOME; MOBILITY LIMITATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SICK LEAVE; TIME FACTORS; UNITED STATES;

EID: 84897876864     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S57157     Document Type: Review

References (27)

1. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2012 Chart Book on Cardiovascular, Lung and Blood Diseases. Bethesda: National Institutes of Health; 2012.
2. Hoyert DL, Xu JQ. Deaths: preliminary data for 2011. Natl Vital Stat Rep. 2012;61(6):1-65.
3. Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation defnition: a review. COPD. 2010;7(3):214-228.
4. Dalal AA, Shah M, D'Souza AO, Rane P. Costs of COPD in the exacerbations in the emergency department and inpatient setting. Respir Med. 2011;105(3):454-460.
5. Wang PS, Beck A, Berglund P, et al. Chronic medical conditions and work performance in the health and work performance questionnaire calibration surveys. J Occup Environ Med. 2003;45(12):1303-1311.
6. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2009 Chart Book on Cardiovascular, Lung and Blood Diseases. Bethesda: National Institutes of Health; 2009.
7. US Bureau of Labor Statistics [webpage on the Internet]. Measuring price change for medical care in the CPI. NE Washington: US Bureau of Labor Statistics; 2010. Available from: http://www.bls.gov/cpi/cpifact4. htm. Accessed February 7, 2014.
8. Ward MM, Jasvitz HS, McFate Smith W, Whan MA. Lost income and work limitations in persons with chronic respiratory disorders. J Clin Epidemiol. 2002;55(3):260-268.
9. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000. MMWR Surveill Summ. 2002;51(6):1-16.
10. Sin DS, Stafnski T, Ng YC, Bell NR, Jacobs P. The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med. 2002;165(5):704-747.
11. Halpern MT, Stanford RH, Borker R. The burden of COPD in the USA: results from the Confronting COPD survey. Respir Med. 2003; 97(Suppl C): S81-S89.
12. DiBonaventura MD, Paulose-Ram R, McDonald M, et al. The impact of COPD on quality of life, productivity loss, and resource use among the elderly United States workforce. J COPD. 2012;9(1):46-57.
13. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The cost of treating COPD in the United States. Chest. 2001;119(2):344-352.
14. Nair K, Ghushchyan V, Van Den Bos J, et al. Burden of illness for an employed population with chronic obstructive pulmonary disease. Pop Health Mgmt. 2012;15(5):267-275.
15. Darkow T, Kadlubek PJ, Hemal S, Phillips AL, Marton J P. A retrospective analysis of disability and its related costs among employees with chronic obstructive pulmonary disease. J Occup Environ Med. 2007;49(1):22-30.
16. Leigh J P, Romano PS, Schenker MB, Kreiss K. Costs of occupational COPD and asthma. Chest. 2002;121(1):264-272.
17. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the "top 10" physical and mental health conditions affecting six large US employers in 1999. J Occup Environ Med. 2003;45(1):5-14.
18. Williams SJ, Bury MR, "Breathtaking": the consequences of chronic respiratory disorder. Int Disabil Stud. 1989;11(3):114-120.
19. Yawn B P, Raphiou I, Hurley JS, Dalal AA. The role of futicasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:165-178.
20. Dalal AA, Shah M, Lunacsek O, Hanania NA. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care organization. COPD. 2011;8(4): 293-299.
21. Dalal AA, Shah M, Lunacsek O, Hanania NA. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Med. 2011;105(10):1516-1522.
22. Peytremann-Bridevaux I, Staeger P, Bridevaux PO, Ghali WA, Burnand B. Effectiveness of chronic obstructive pulmonary disease-management programs: A systematic review and meta-analysis. Am J Med. 2008;121:433-443.
23. Lemmens KM, Nieboer A P, Huijsman R. A systematic review of integrated use of disease-management interventions in asthma and COPD. Respir Med. 2009;103(5):670-691.
24. Dewan NA, Rice KL, Caldwell M, Hilleman DE. Economic evaluation of a disease management program for chronic obstructive pulmonary disease. COPD. 2011;8(3):153-159.
25. Pinto-Plata V, Divo M, Celli BR. Treatments to alter the natural history of COPD. Pulmonary, Critical Care, Sleep Update (PCCSU). 2010;24, lesson 10.
26. Global Strategy for Diagnosis, Management, and Prevention of COPD. Global Initiative for Chronic Obstructive Pulmonary Disease. 2014. Available from: http://www.goldcopd.org/uploads/users/fles/ GOLD_Report2014_Feb07.pdf. Accessed February 7, 2014.
27. Restrepo RD. A stepwise approach to management of stable COPD with inhaled pharmacotherapy: a review. Respir Care. 2009;54(8): 1058-1081.